A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Reduced Ejection Fraction (HFrEF) (EMPERIAL-reduced)
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms EMPERIAL-reduced
- Sponsors Boehringer Ingelheim
- 17 Oct 2019 Status changed from active, no longer recruiting to completed.
- 11 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2019 Planned End Date changed from 6 Dec 2019 to 3 Oct 2019.